Civic AI
Procurement intelligence
Federal contract award
PRECLINICAL EFFICACY & INTERMEDIATE ENDPOINT BIOMARKERS IDIQ CONTRACT IN SUPPORT OF THE PREVENT CANCER PRECLINICAL DRUG DEVELOPMENT PROGRAM
THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER · Department of Health and Human Services
- Value
- $0
- Start
- Jan 25, 2024
- End
- —
- Action date
- May 12, 2026
- PIID
- 75N91024D00004
- Status
- active
- NAICS
- 541714 · RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY (EXCEPT NANOBIOTECHNOLOGY)
- Place of performance
- —
- Award type
- —
Description
PRECLINICAL EFFICACY & INTERMEDIATE ENDPOINT BIOMARKERS IDIQ CONTRACT IN SUPPORT OF THE PREVENT CANCER PRECLINICAL DRUG DEVELOPMENT PROGRAM
Need modifications, related awards, and vendor peers? Open the full award workspace.